Related Experiment Videos
[Experimental study of the myelotoxic effect of tomizine]
Abstract:
In tests conducted on 220 rats with transplantable sarcoma M-1 and intact animals acute toxicity, antineoplastic effect and the action on the blood system of tomizine, a new neoplastic drug of the group of the folic acid antagonists, were studied. Investigation involved a single intraperitoneal injection of the drug in DL50/30 and MTD. The compound is shown to exert an inhibiting action on the development of sarcoma M-1 and lengthens the survival of the tumour-stricken animals, without producing any pronounced myelotoxic effect. The disclosed shifts on the level of the periphedal blood and marrow were short-lived and concerned mainly the erythroid germ cells.
Insights
Tomizine, a novel folic acid antagonist, effectively inhibits sarcoma M-1 growth in rats. This new anticancer drug prolongs survival without significant myelotoxicity, showing only temporary effects on blood and marrow cells.
Area of Science:
- Pharmacology
- Oncology
- Toxicology
Background:
- Folic acid antagonists are a class of antineoplastic drugs.
- Sarcoma M-1 is a transplantable tumor model used in preclinical cancer research.
- Understanding the toxicity and efficacy of new anticancer agents is crucial.
Purpose of the Study:
- To evaluate the acute toxicity, antineoplastic effect, and impact on the blood system of tomizine.
- To assess tomizine's efficacy against transplantable sarcoma M-1 in rats.
- To determine the safety profile of tomizine concerning myelotoxicity.
Main Methods:
- Acute toxicity testing using median lethal dose (DL50/30) and maximum tolerated dose (MTD).
- Administration of tomizine via single intraperitoneal injection in rats.
- Monitoring tumor development, animal survival, and hematological parameters in peripheral blood and bone marrow.
Main Results:
- Tomizine demonstrated a significant inhibitory effect on sarcoma M-1 progression.
- The drug administration led to a notable increase in the survival time of tumor-bearing rats.
- No pronounced myelotoxic effects were observed; transient changes were limited to erythroid progenitor cells.
Conclusions:
- Tomizine exhibits promising antineoplastic activity against sarcoma M-1.
- The drug presents a favorable safety profile with minimal impact on the hematopoietic system.
- Further investigation into tomizine as a potential therapeutic agent for neoplastic diseases is warranted.